Now that disease-modifying therapies are available to treat primary SMA pathologies (e.g., spinal motoneuron dysfunction and loss), secondary defects arising from chronic SMN deficiency in untargeted peripheral tissues may emerge. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.